On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety

Physicist Stephen Hawking lived with amyotrophic lateral sclerosis (ALS) for more than five decades. Diagnosed at 21 in 1963, he was initially given just two years to live. However, his early-onset form of ALS progressed unusually slowly. Hawking died on March 14, 2018, aged 76.

Now, US researchers have developed a personalized RNA therapy for a rare genetic form of ALS and administered it to a single patient. One year after treatment, the patient showed improvements in physical function and a key biomarker of nerve damage.

ALS, also known as motor neuron disease (MND) or Lou Gehrig’s disease, affects nerve cells in the brain and spinal cord that control voluntary movement. As these neurons deteriorate, muscles become progressively weaker and can eventually lead to paralysis.

What Was The New RNA Therapy?

Researchers at the Mayo Clinic developed an antisense oligonucleotide (ASO) therapy, a personalized RNA-based treatment designed to target RNA produced by the mutated gene and reduce the production of specific proteins.

Unlike conventional gene therapy, which aims to alter a person's genetic material, ASO therapy uses short strands of genetic material called “oligonucleotides,” to target RNA, according to the findings, published in the international journal Med.

These oligonucleotides prevent the production of the proteins that cause ALS.

It was administered on the male patient who had slowly progressive ALS, with onset in his right shoulder in 2020. In 2018, he underwent a spine surgery for radiating left neck and arm pain with mild weakness.

It was in 2021 that he was diagnosed with ALS caused by a mutation in the CHCHD10 gene, found in fewer than 1% of people with hereditary ALS.

Defects in CHCHD10 can damage mitochondria, which produce energy inside cells, ultimately contributing to nerve-cell death and ALS.

Patient's ALS Symptoms Improved

The patient received six spinal injections between April 2024 and April 2025. The first three doses were 50 milligrams each, followed by three 75-milligram doses.

One year after the first dose, the patient's blood levels of neurofilament light chain (NfL) had fallen by about 50% and returned to the normal reference range.

NfL is a protein released when nerve cells are damaged and is used as a biomarker of neurodegeneration and ALS progression.

The patient's score on the Revised ALS Functional Rating Scale (ALSFRS-R) also increased from 33 to 36 over the year. The scale measures physical function in people with ALS.

Other measures of breathing and cognition remained stable, and the patient showed no signs of cognitive decline during the reported follow-up.

"To date, the ASO has been well tolerated, with a good safety profile, and has demonstrated early signs of efficacy. The patient reports subjective improvement, and our primary response biomarker, neurofilament light (NfL), has normalized," the research team wrote in the paper.

The patient’s symptoms improved one year after receiving the drug, and he continues to work as a physician, Nature reported.

“We have shown that it is possible to develop a personalized ASO therapy for CHCHD10-related ALS,” adding that this provides “evidence suggesting the potential for therapeutic benefit in the clinic,” the research team stated.

Is This A Cure For ALS?

The findings are an early step, and it is far too soon to know whether the treatment can stop ALS progression or provide a cure.

The patient will need to be monitored for several more years, while the therapy must also be tested in additional patients to determine whether the improvements can be sustained and whether the treatment can slow disease progression.

A new clinical trial published by The Lancet says that HIV treatment through two injections every eight weeks kept the virus suppressed more effectively than daily tablets among adolescents, calling for efforts to make this treatment available and accessible worldwide.

Also Read: ‘Zombie’ Drug Medetomidine, Spotted In Heroin Supply, Raises Concern As It Could Evade Overdose Antidote

The LATA trial, led by a team of researchers at University College London (UCL), examined 476 adolescents aged between 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe.

Participants were randomly assigned to continue daily antiretroviral tablets or switch to injections containing cabotegravir and rilpivirine.

All participants had already been taking HIV treatment for more than a year, had an undetectable amount of viral load and had no history of treatment failure. Most of the participants had acquired HIV at birth.

HIV Injections Prevented Viral Rebound

After 96 weeks, just two adolescents showed confirmed viral rebound, or 1%, in the injectable-treatment group. Comparatively, 15 adolescents, or 6%, among those taking daily tablets showed viral rebound. Viral rebound refers to the levels of HIV in the blood that increases again after being suppressed previously.

Maintaining an undetectable viral load is central to HIV treatment. It also reduces the risk of sexual transmission significantly.

The researchers found that the injectable treatment was not only effective at maintaining viral suppression but was preferred by adolescents.

Around 94% of participants receiving the injections said treatment every eight weeks was much easier and more convenient than taking medicine every day.

Professor Sarah Pett, chief investigator of the LATA trial at UCL, said, “HIV-positive adolescents as a group have historically done worse on antiretrovirals compared to adults. There is bullying and stigma associated with taking pills every day. Long-acting injectables taken every two months can help young people lead a more normal life.”

She added that the benefits seen in adolescents were stronger than previously observed in adults, where trials have generally shown that injections are no less effective than daily tablets.

Also read: Exclusive With Leading HIV Expert: What's Driving Rising HIV Cases Among India's Youth And How To Prevent It

Could Injections Help Treat HIV Better In Young People?

Taking HIV pills every day can be difficult for adolescents, particularly when its treatment is associated with stigma. They may have concerns about others discovering their HIV status, which could challenge the maintenance of a daily routine.

The weekly-injection approach removes the need to remember to take a pill every day. Instead, cabotegravir and rilpivirine are administered in a healthcare setting once every eight weeks. This could be particularly relevant in Africa, where most adolescents living with HIV reside.

“Nine out of 10 adolescents with HIV live in Africa, yet currently this treatment is not accessible to them,” Pett said.

Also read: Once-Weekly Oral Combination HIV Pill Shows Promise As Alternative to Daily Treatment

Accessibility To The Treatment Is Still A Challenge

Despite the promising results, researchers say that access to the groundbreaking treatment still remains a major challenge.

The HIV injections are more expensive than standard tablets as they remain under patent. Rilpivirine also requires refrigeration during storage and transport. Trained healthcare workers are needed to administer the injections every eight weeks.

The World Health Organization currently recommends that the injectable treatment must be used as an alternative for adults and adolescents who have successfully suppressed HIV on oral treatment as well as do not have active hepatitis B.

Dr Deborah Ford of UCL said, “The lack of availability of injectable treatments in Africa risks increasing inequalities in HIV care, leaving most people living with HIV without access to treatments that are available in high-income settings.”

A powerful veterinary drug has been lately spotted in Scotland's illegal drug supply, raising concern among health officials and addiction specialists about severe sedation, overdose-related deaths and dangerous withdrawal symptoms.

Medically known as medetomidine, the drug is used by veterinarians to sedate animals. It is strictly not approved for use in humans.

According to Public Health Scotland, the drug has been located in Scotland's unlawful drug supply and is most likely being mixed into drugs and peddled as heroin and benzodiazepines.

According to recent reports, medetomidine was detected in one in five heroin samples tested between March and June 2026, highlighting it has seeped deeply into various parts of the drug supply. It has been detected in several areas, including Lanarkshire, Falkirk, Dundee, Fife and the Highlands.

Also read: Alzheimer's Day: Why Can A Patient Remember An Event From Decades Ago But Forget What Happened This Morning?

What Is Medetomidine?

Medetomidine is a sedative that affects the alpha-2 receptors in the nervous system, producing profound sedation and slowing down several bodily functions, rendering the user in a ‘zombie-like’ state.

The UK's Advisory Council on the Misuse of Drugs has previously warned that medetomidine can cause severe sedation, reduced heart rate and other negative cardiovascular effects. In severe toxicity, people may require intensive care and mechanical ventilation.

Unlike an opioid overdose, naloxone does not reverse medetomidine's sedative effects. This is particularly concerning as the drug was found mixed with opioids like heroin.

Also read: US Teen's Death Sparks Warning Over Synthetic Drug Deadlier Than Fentanyl

Why Is It Being Called A ‘Zombie’ Drug?

The drug is being called a ‘zombie drug’ due to the effects it leaves due to excessive sedation and changed behaviour. After ingesting it, people may become extremely drowsy or unresponsive, while others may experience confusion, hallucinations or agitation. It may also slow their movements and reflexes down.

The bigger concern is the aftereffects of exposure. A recent study of 16 people with confirmed medetomidine exposure found that patients reported severe and unpredictable withdrawal symptoms, sometimes requiring hospital treatment.

Symptoms reported in the study included nausea, vomiting, shaking, rapid heartbeat, and dangerous high blood pressure.

Researchers also found that standard medications used to treat opioid withdrawal did not always adequately control the symptoms linked with medetomidine.

Also read: Donald Trump Wants Childhood Vaccines Split Into 5 Shots To Prevent Autism: But Is There Evidence?

More About The Drug

Public Health Scotland says that the drug has been detected in brown powders sold as heroin and white tablets sold as diazepam. As people may believe they are taking another drug, they may have no idea that a potent veterinary sedative is also entering their body. This could make tracking the drug supply difficult to predict.

Medetomidine belongs to the same broad class as xylazine, another veterinary sedative that has been increasingly detected in illegal drugs.

Xylazine has become notorious in the US for severe skin wounds linked with repeated exposure. Scientists do not yet know whether medetomidine results in the same effect in humans.